Structure-based Virtual Screening and Identification of a Novel Androgen Receptor Antagonist*

Background: The androgen receptor (AR) is the primary drug target for prostate cancer treatment. Results: We have identified a novel AR antagonist, the compound 6-(3,4-dihydro-1H-isoquinolin-2-yl)-N-(6-methylpyridin-2-yl)nicotinamide (DIMN) that inhibits the growth of AR-positive prostate cancer cells. Conclusion: DIMN has been identified as a new lead structure targeting the AR. Significance: This novel AR antagonist could be a useful therapeutic agent for prostate cancer treatment. Hormonal therapies, mainly combinations of anti-androgens and androgen deprivation, have been the mainstay treatment for advanced prostate cancer because the androgen-androgen receptor (AR) system plays a pivotal role in the development and progression of prostate cancers. However, the emergence of androgen resistance, largely due to inefficient anti-hormone action, limits the therapeutic usefulness of these therapies. Here, we report that 6-(3,4-dihydro-1H-isoquinolin-2-yl)-N-(6-methylpyridin-2-yl)nicotinamide (DIMN) acts as a novel anti-androgenic compound that may be effective in the treatment of both androgen-dependent and androgen-independent prostate cancers. Through AR structure-based virtual screening using the FlexX docking model, fifty-four compounds were selected and further screened for AR antagonism via cell-based tests. One compound, DIMN, showed an antagonistic effect specific to AR with comparable potency to that of the classical AR antagonists, hydroxyflutamide and bicalutamide. Consistent with their anti-androgenic activity, DIMN inhibited the growth of androgen-dependent LNCaP prostate cancer cells. Interestingly, the compound also suppressed the growth of androgen-independent C4–2 and CWR22rv prostate cancer cells, which express a functional AR, but did not suppress the growth of the AR-negative prostate cancer cells PPC-1, DU145, and R3327-AT3.1. Taken together, the results suggest that the synthetic compound DIMN is a novel anti-androgen and strong candidate for useful therapeutic agent against early stage to advanced prostate cancer.

• Publication year

  2012

• Venue

  Journal of Biological Chemistry

• Publication date

  2012-07-13

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1074/jbc.M112.379107PMID 22798067PMCID PMC3436320
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Biological properties of androgen receptor pure antagonist for treatment of castration‐resistant prostate cancer: Optimization from lead compound to CH5137291

  2011cited by this paper
• Inhibitors of androgen receptor activation function-2 (AF2) site identified through virtual screening.

  2011cited by this paper
• MAP Kinases and Prostate Cancer

  2011cited by this paper
• Mechanism of androgen receptor antagonism by bicalutamide in the treatment of prostate cancer.

  2011influential reference
• Global cancer statistics

  2011cited by this paper
• Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC).

  2010cited by this paper
• Limitations of MTT and MTS-Based Assays for Measurement of Antiproliferative Activity of Green Tea Polyphenols

  2010cited by this paper
• Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor.

  2010cited by this paper
• Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines

  2010cited by this paper
• Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.

  2009cited by this paper
• Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit.

  2009cited by this paper
• HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer.

  2009cited by this paper
• Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

  2009cited by this paper
• Computationally Identified Novel Diphenyl- and Phenylpyridine Androgen Receptor Antagonist Structures

  2008cited by this paper
• Cancer Statistics, 2008

  2008cited by this paper
• Hepatocyte nuclear factor-3 alpha (HNF-3alpha) negatively regulates androgen receptor transactivation in prostate cancer cells.

  2008cited by this paper
• Reduced testicular steroidogenesis in tumor necrosis factor-alpha knockout mice.

  2008cited by this paper
• CR6-interacting factor 1 represses the transactivation of androgen receptor by direct interaction.

  2008cited by this paper
• Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival

  2008cited by this paper
• AKT regulates androgen receptor-dependent growth and PSA expression in prostate cancer.

  2008cited by this paper
• A novel synthetic compound that interrupts androgen receptor signaling in human prostate cancer cells

  2007cited by this paper
• Antiandrogens in the treatment of prostate cancer.

  2007cited by this paper
• Crystal Structure of the T877A Human Androgen Receptor Ligand-binding Domain Complexed to Cyproterone Acetate Provides Insight for Ligand-induced Conformational Changes and Structure-based Drug Design*

  2007cited by this paper
• Evaluation of an in vitro model of androgen ablation and identification of the androgen responsive proteome in LNCaP cells

  2007cited by this paper
• Preclinical Pharmacology of a Nonsteroidal Ligand for Androgen Receptor-Mediated Imaging of Prostate Cancer

  2006cited by this paper
• (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist.

  2006cited by this paper
• The corepressors silencing mediator of retinoid and thyroid hormone receptor and nuclear receptor corepressor are involved in agonist- and antagonist-regulated transcription by androgen receptor.

  2006cited by this paper
• The CCAAT enhancer-binding protein-alpha negatively regulates the transactivation of androgen receptor in prostate cancer cells.

  2006cited by this paper
• Pharmacokinetics and Pharmacodynamics of Nonsteroidal Androgen Receptor Ligands

  2006cited by this paper
• The CCAAT Enhancer-Binding Protein-α Negatively Regulates the Transactivation of Androgen Receptor in Prostate Cancer Cells

  2006cited by this paper
• Current thoughts on the role of the androgen receptor and prostate cancer progression.

  2005cited by this paper
• Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.

  2005cited by this paper
• Targeting the androgen receptor in hormone-refractory prostate cancer--new concepts.

  2005influential reference
• Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.

  2005cited by this paper
• N-Arylpiperazine-1-carboxamide derivatives: a novel series of orally active nonsteroidal androgen receptor antagonists.

  2005cited by this paper
• Comparative Effects of Bicalutamide (Casodex) versus Orchidectomy on Bone Mineral Density, Bone Remodelling, and Bone Biomechanics in Healthy Rats

  2005cited by this paper
• Global Cancer Statistics, 2002

  2005cited by this paper
• Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists.

  2005cited by this paper
• Modulation of the expression and transactivation of androgen receptor by the basic helix-loop-helix transcription factor Pod-1 through recruitment of histone deacetylase 1.

  2005cited by this paper
• Structural Basis for Accommodation of Nonsteroidal Ligands in the Androgen Receptor*

  2005cited by this paper
• Structural basis for antagonism and resistance of bicalutamide in prostate cancer

  2005cited by this paper
• Molecular determinants of resistance to antiandrogen therapy

  2004cited by this paper
• Androgen deprivation therapy for prostate cancer: Current status and future prospects

  2004cited by this paper
• Androgen receptor in prostate cancer.

  2004cited by this paper
• Prostate specific antigen gene regulation by androgen receptor

  2004cited by this paper
• Ras signaling in prostate cancer progression

  2004cited by this paper
• Mechanistic Concepts in Androgen-dependence of Prostate Cancer

  2004cited by this paper
• Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer.

  2004cited by this paper
• Androgen Receptor Coregulators in Prostate Cancer

  2004cited by this paper
• Antiandrogens in Prostate Cancer

  2004cited by this paper
• Expression of MIS in the testis is downregulated by tumor necrosis factor alpha through the negative regulation of SF-1 transactivation by NF-kappa B.

  2003cited by this paper
• PTEN: One Gene, Many Syndromes

  2003cited by this paper
• Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.

  2003cited by this paper
• The role of antiandrogen monotherapy in the treatment of prostate cancer

  2003cited by this paper
• Expression of MIS in the Testis Is Downregulated by Tumor Necrosis Factor Alpha through the Negative Regulation of SF-1 Transactivation by NF-κB

  2003cited by this paper
• The embedded tumour: host physiology is important for the evaluation of tumour growth

  2003cited by this paper
• Antiandrogenic effects of bisphenol A and nonylphenol on the function of androgen receptor.

  2003cited by this paper
• Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.

  2003cited by this paper
• Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer

  2003cited by this paper
• Stabilization of androgen receptor protein is induced by agonist, not by antagonists.

  2002influential reference
• Bicalutamide Functions as an Androgen Receptor Antagonist by Assembly of a Transcriptionally Inactive Receptor*

  2002influential reference
• Evidence that chlormadinone acetate exhibits antiandrogenic activity in androgen-dependent cell line.

  2002cited by this paper
• Androgen receptor expression is regulated by the phosphoinositide 3-kinase/Akt pathway in normal and tumoral epithelial cells.

  2002cited by this paper
• Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation.

  2002cited by this paper
• The program of androgen-responsive genes in neoplastic prostate epithelium

  2002cited by this paper
• Androgen receptor (AR) coregulators: an overview.

  2002cited by this paper
• Mechanism of antiandrogen action: key role of hsp90 in conformational change and transcriptional activity of the androgen receptor.

  2002cited by this paper
• Phosphatidylinositol 3-Kinase/Akt Stimulates Androgen Pathway through GSK3β Inhibition and Nuclear β-Catenin Accumulation*

  2002cited by this paper
• Activating Signal Cointegrator 1 Is Highly Expressed in Murine Testicular Leydig Cells and Enhances the Ligand-Dependent Transactivation of Androgen Receptor1

  2002cited by this paper
• From transforming growth factor-beta signaling to androgen action: identification of Smad3 as an androgen receptor coregulator in prostate cancer cells.

  2001cited by this paper
• Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor

  2001cited by this paper
• The development of androgen-independent prostate cancer

  2001cited by this paper
• From transforming growth factor-β signaling to androgen action: Identification of Smad3 as an androgen receptor coregulator in prostate cancer cells

  2001cited by this paper
• A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy.

  2001cited by this paper
• Pregnenolone stimulates LNCaP prostate cancer cell growth via the mutated androgen receptor.

  2000cited by this paper
• LNCaP progression model of human prostate cancer: Androgen‐independence and osseous metastasis

  2000cited by this paper
• Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations.

  2000cited by this paper
• HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway.

  2000cited by this paper
• Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.

  2000cited by this paper
• Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system

  1999cited by this paper
• From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells.

  1999cited by this paper
• Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.

  1999cited by this paper
• A Nuclear Factor, ASC-2, as a Cancer-amplified Transcriptional Coactivator Essential for Ligand-dependent Transactivation by Nuclear Receptors in Vivo *

  1999cited by this paper
• Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone.

  1999cited by this paper
• Molecular action of androgen in the normal and neoplastic prostate.

  1999cited by this paper
• Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells.

  1998cited by this paper
• From estrogen to androgen receptor: a new pathway for sex hormones in prostate.

  1998cited by this paper
• Intermolecular NH2-/Carboxyl-terminal Interactions in Androgen Receptor Dimerization Revealed by Mutations That Cause Androgen Insensitivity*

  1998influential reference
• Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes.

  1998cited by this paper
• Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression.

  1998cited by this paper
• Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells.

  1997cited by this paper
• GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors

  1997cited by this paper
• The androgen receptor in prostate cancer.

  1996cited by this paper
• Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor.

  1995cited by this paper
• In vivo amplification of the androgen receptor gene and progression of human prostate cancer

  1995cited by this paper
• Hormone-refractory (D3) prostate cancer: refining the concept.

  1995cited by this paper
• Synthesis and Biological Activity of Novel Nonsteroidal Progesterone Receptor Antagonists

  1995cited by this paper
• Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor Superfamily

  1995cited by this paper
• Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.

  1994cited by this paper
• Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone.

  1993cited by this paper

• A potent new-scaffold androgen receptor antagonist discovered on the basis of a MIEC-SVM model

  2024cites this paper
• Androgen receptor inhibitors in treating prostate cancer

  2024cites this paper
• Structure-based discovery of pyrazolamides as novel ERRγ inverse agonists.

  2023cites this paper
• Identification of ligands binding to MB327-PAM-1, a binding pocket relevant for resensitization of nAChRs

  2023cites this paper
• JAG1 Intracellular Domain Enhances AR Expression and Signaling and Promotes Stem-like Properties in Prostate Cancer Cells

  2022cites this paper
• Emerging Promise of Computational Techniques in Anti-Cancer Research: At a Glance

  2022cites this paper
• In silico comparison between the mutated and wild-type androgen receptors and their influence on the selection of optimum androgenic receptor blockers for the treatment of prostate cancer

  2022cites this paper
• In silico comparison between the mutated and wild type androgen receptors and their influence on the selection of optimum androgenic receptor blocker for treatment of prostate cancer

  2022cites this paper
• Disruption of androgen receptor signaling by chlorpyrifos (CPF) and its environmental degradation products: a structural insight

  2021cites this paper
• Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.

  2021cites this paper
• Microwave-assisted synthesis of fluoroorganics

  2021cites this paper
• Molecular Docking Study of Mangosteen (Garcinia mangostana L.) Xanthone-Derived Isolates as Anti Androgen

  2021cites this paper
• A new compound targets the AF-1 of androgen receptor and decreases its activity and protein levels in prostate cancer cells.

  2020cites this paper
• Novel androgen receptor antagonist identified by structure-based virtual screening, structural optimization, and biological evaluation.

  2020cites this paper
• Quantitative structure-activity relationships study of a series of niacinamide analogues as androgen receptor antagonists

  2020cites this paper
• Advances in the computational development of androgen receptor antagonists.

  2020cites this paper
• A magic drug target: Androgen receptor

  2019cites this paper
• Computational Assessment of the Pharmacological Profiles of Degradation Products of Chitosan

  2019cites this paper
• Non-Steroidal Androgen Receptor Antagonists and Prostate Cancer: a Survey on Chemical Structures Binding this Fast-Mutating Target.

  2019cites this paper
• Discovery of Novel Androgen Receptor Ligands by Structure-based Virtual Screening and Bioassays

  2018influential citation
• Novel aryl piperazines for alleviation of 'andropause' associated prostatic disorders and depression.

  2017cites this paper
• 7-Substituted umbelliferone derivatives as androgen receptor antagonists for the potential treatment of prostate and breast cancer.

  2016cites this paper
• Convenient Access to Di‐ and Tri­fluoroethylamines for Lead Structure Research

  2016cites this paper
• 6-(3,4-Dihydro-1H-isoquinoline-2-yl)-N-(6-methoxypyridine-2-yl) nicotinamide-26 (DIMN-26) decreases cell proliferation by induction of apoptosis and downregulation of androgen receptor signaling in human prostate cancer cells.

  2016cites this paper
• Design and synthesis of novel androgen receptor antagonists via molecular modeling.

  2016cites this paper
• Progress in antiandrogen design targeting hormone binding pocket to circumvent mutation based resistance

  2015cites this paper
• Corrigendum: Progress in antiandrogen design targeting hormone binding pocket to circumvent mutation based resistance

  2015cites this paper
• Ligand-Based Virtual Screening in a Search for Novel Anti-HIV-1 Chemotypes

  2015cites this paper
• Virtual screening strategies: recent advances in the identification and design of anti-cancer agents.

  2015cites this paper
• Discovery of novel androgen receptor inhibitors as prospective therapeutics for advanced prostate cancer

  2015cites this paper
• Impact of low molecular weight phthalates in inducing reproductive malfunctions in male mice: Special emphasis on Sertoli cell functions.

  2015cites this paper
• A new avenue toward androgen receptor pan-antagonists: C2 sterically hindered substitution of hydroxy-propanamides.

  2014cites this paper
• Androgen receptor: structure, role in prostate cancer and drug discovery

  2014cites this paper
• Enhancement of the Tumor Penetration of Monoclonal Antibody by Fusion of a Neuropilin-Targeting Peptide Improves the Antitumor Efficacy

  2014cites this paper
• Expression profiles and functional associations of endogenous androgen receptor and caveolin‐1 in prostate cancer cell lines

  2014cites this paper
• Design and Synthesis of 4-(4-Benzoylaminophenoxy)phenol Derivatives As Androgen Receptor Antagonists.

  2013cites this paper
• SAR based design of nicotinamides as a novel class of androgen receptor antagonists for prostate cancer.

  2013cites this paper
• Identification of Novel Androgen Receptor Antagonists Using Structure- and Ligand-Based Methods

  2013cites this paper
• Ligand Pose and Orientational Sampling in Molecular Docking

  2013cites this paper
• Targeting Alternative Sites on the Androgen Receptor to Treat Castration-Resistant Prostate Cancer

  2013cites this paper
• Androgen receptor in human health: a potential therapeutic target.

  2012cites this paper